PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19139319-1 2009 BACKGROUND: Animal data on cardiac arrest showed improved long-term survival with combined vasopressin-epinephrine. Epinephrine 103-114 arginine vasopressin Homo sapiens 91-102 18591701-1 2008 PURPOSE: To report the use of vasopressin to treat a patient who, after failing to respond to volume expansion and epinephrine administration, experienced an anaphylactic reaction to rocuronium. Epinephrine 115-126 arginine vasopressin Homo sapiens 30-41 18591701-9 2008 CONCLUSIONS: Vasopressin may be effective in the resuscitation of anesthetized patients, with hemodynamic instability associated with anaphylaxis resistant to epinephrine and alpha-agonists. Epinephrine 159-170 arginine vasopressin Homo sapiens 13-24 18467889-9 2008 Arginine vasopressin may be considered in patients presenting with asystole or who are unresponsive to initial treatment with epinephrine. Epinephrine 126-137 arginine vasopressin Homo sapiens 9-20 16931995-6 2006 During cardiopulmonary resuscitation, a 40-U bolus dose of vasopressin may be considered to replace the first or second bolus of epinephrine regardless of the initial rhythm. Epinephrine 129-140 arginine vasopressin Homo sapiens 59-70 18252001-6 2008 CONCLUSION: In case of anaphylactic shock, continuous infusion of low-dose vasopressin might be considered after inadequate response to epinephrine, fluid resuscitation and corticosteroid administration. Epinephrine 136-147 arginine vasopressin Homo sapiens 75-86 17376225-6 2007 Final end-tidal carbon dioxide values and average values of MAP in patients with restoration of pulse were significantly higher in the vasopressin/epinephrine group (p < 0.01). Epinephrine 147-158 arginine vasopressin Homo sapiens 135-146 17376225-13 2007 Resuscitated patients treated with vasopressin alone or followed by epinephrine have higher average and final end-tidal carbon dioxide values as well as a higher MAP on admission to the hospital than patients treated with epinephrine only. Epinephrine 222-233 arginine vasopressin Homo sapiens 35-46 17134621-1 2006 Vasopressin administration has been suggested during cardiopulmonary resuscitation, and a previous clinical trial has suggested that vasopressin is most effective when administered with epinephrine. Epinephrine 186-197 arginine vasopressin Homo sapiens 133-144 17134621-0 2006 Usefulness of vasopressin administered with epinephrine during out-of-hospital cardiac arrest. Epinephrine 44-55 arginine vasopressin Homo sapiens 14-25 15985820-9 2005 Case reports support the use of the vasoconstrictors metaraminol, methoxamine and vasopressin if adrenaline is ineffective. Epinephrine 97-107 arginine vasopressin Homo sapiens 82-93 16552222-5 2006 Arginine vasopressin has been shown to be as effective as epinephrine in patients with ventricular fibrillation and pulseless electrical activity, and may be more effective in patients presenting with asystole or as the second vasopressor (after epinephrine) in refractory cardiac arrest. Epinephrine 246-257 arginine vasopressin Homo sapiens 9-20 16534265-3 2005 A multicentre trial compared arginine vasopressin and epinephrine in out-of-hospital cardiac arrest, and documented a significant improvement in hospital discharge rates in arginine vasopressin-treated (up to 2 x 40 IU) patients with asystole, and a significant benefit of the combined administration of arginine vasopressin and epinephrine on hospital discharge, irrespective of the underlying electrocardiographic rhythm. Epinephrine 54-65 arginine vasopressin Homo sapiens 182-193 16534265-3 2005 A multicentre trial compared arginine vasopressin and epinephrine in out-of-hospital cardiac arrest, and documented a significant improvement in hospital discharge rates in arginine vasopressin-treated (up to 2 x 40 IU) patients with asystole, and a significant benefit of the combined administration of arginine vasopressin and epinephrine on hospital discharge, irrespective of the underlying electrocardiographic rhythm. Epinephrine 54-65 arginine vasopressin Homo sapiens 182-193 16552222-10 2006 Arginine vasopressin may be considered in patients presenting with asystole or who are unresponsive to initial treatment with epinephrine. Epinephrine 126-137 arginine vasopressin Homo sapiens 9-20 16542483-3 2006 A subgroup analysis of a large prospective CPR investigation and of retrospective CPR studies suggests that vasopressin may be especially beneficial when combined with epinephrine. Epinephrine 168-179 arginine vasopressin Homo sapiens 108-119 15774080-7 2005 Vasopressin has been shown to result in greater blood flow diversion from nonvital to vital organ beds compared with adrenaline (epinephrine). Epinephrine 129-140 arginine vasopressin Homo sapiens 0-11 15131912-4 2004 Vasopressin, like epinephrine, promotes selective but potent vasoconstriction of smooth muscle, but unlike epinephrine, without the potentially harmful side effects of increasing myocardial workload, therefore increasing oxygen demand and subsequent worsening of cardiac function. Epinephrine 18-29 arginine vasopressin Homo sapiens 0-11 15616384-7 2004 In hypodynamic animal models of sepsis vasopressin compromised oxygen delivery and decreased systemic and gut blood flow.High-dose bolus vasopressin appeared promising in animal studies of hemorrhagic shock and cardiopulmonary arrest and in a large, randomized clinical trial of vasopressin versus epinephrine in human cardiopulmonary arrest with asystole. Epinephrine 298-309 arginine vasopressin Homo sapiens 137-148 15616384-7 2004 In hypodynamic animal models of sepsis vasopressin compromised oxygen delivery and decreased systemic and gut blood flow.High-dose bolus vasopressin appeared promising in animal studies of hemorrhagic shock and cardiopulmonary arrest and in a large, randomized clinical trial of vasopressin versus epinephrine in human cardiopulmonary arrest with asystole. Epinephrine 298-309 arginine vasopressin Homo sapiens 137-148 15508673-9 2004 Vasopressin followed by epinephrine was more effective than epinephrine alone in the treatment of refractory cardiac arrest. Epinephrine 60-71 arginine vasopressin Homo sapiens 0-11 15582762-0 2004 Vasopressin administered with epinephrine is associated with a return of a pulse in out-of-hospital cardiac arrest. Epinephrine 30-41 arginine vasopressin Homo sapiens 0-11 15582762-11 2004 Subjects receiving vasopressin and epinephrine were more likely to have a return of pulses during the resuscitation (LR: 2.73; 95% CI: 1.24, 6.03) and at hospital arrival (3.85; 1.71, 8.65) than subjects treated with epinephrine alone. Epinephrine 217-228 arginine vasopressin Homo sapiens 19-30 17021455-6 2003 Clinical experience on the use of vasopressin for in-hospital cardiopulmonary resuscitation with short response time showed equipotency with epinephrine; in patients with out-of-hospital ventricular fibrillation, vasopressin showed improved 24 h survival in comparison with epinephrine. Epinephrine 141-152 arginine vasopressin Homo sapiens 34-45 14711909-8 2004 Among patients with asystole, however, vasopressin use was associated with significantly higher rates of hospital admission (29.0 percent, vs. 20.3 percent in the epinephrine group; P=0.02) and hospital discharge (4.7 percent vs. 1.5 percent, P=0.04). Epinephrine 163-174 arginine vasopressin Homo sapiens 39-50 14711909-9 2004 Among 732 patients in whom spontaneous circulation was not restored with the two injections of the study drug, additional treatment with epinephrine resulted in significant improvement in the rates of survival to hospital admission and hospital discharge in the vasopressin group, but not in the epinephrine group (hospital admission rate, 25.7 percent vs. 16.4 percent; P=0.002; hospital discharge rate, 6.2 percent vs. 1.7 percent; P=0.002). Epinephrine 137-148 arginine vasopressin Homo sapiens 262-273 17021455-6 2003 Clinical experience on the use of vasopressin for in-hospital cardiopulmonary resuscitation with short response time showed equipotency with epinephrine; in patients with out-of-hospital ventricular fibrillation, vasopressin showed improved 24 h survival in comparison with epinephrine. Epinephrine 274-285 arginine vasopressin Homo sapiens 34-45 17021455-6 2003 Clinical experience on the use of vasopressin for in-hospital cardiopulmonary resuscitation with short response time showed equipotency with epinephrine; in patients with out-of-hospital ventricular fibrillation, vasopressin showed improved 24 h survival in comparison with epinephrine. Epinephrine 274-285 arginine vasopressin Homo sapiens 213-224 11953644-5 2002 In patients who experienced out-of-hospital ventricular fibrillation, a larger proportion of patients treated with vasopressin survived 24 hrs compared with patients treated with epinephrine; during in-hospital cardiopulmonary resuscitation, comparable short-term survival was found in groups treated with either vasopressin or epinephrine. Epinephrine 328-339 arginine vasopressin Homo sapiens 115-126 14509133-2 2003 The administration of exogenous vasopressin during closed and open cardiopulmonary resuscitation in humans was shown to be more effective than optimal doses of epinephrine in several clinical studies. Epinephrine 160-171 arginine vasopressin Homo sapiens 32-43 12006787-12 2002 CONCLUSIONS: In this pediatric porcine model of ventricular fibrillation, the combination of epinephrine with vasopressin during cardiopulmonary resuscitation resulted in significantly higher levels of left ventricular myocardial blood flow than either vasopressin alone or epinephrine alone. Epinephrine 93-104 arginine vasopressin Homo sapiens 253-264 12006787-12 2002 CONCLUSIONS: In this pediatric porcine model of ventricular fibrillation, the combination of epinephrine with vasopressin during cardiopulmonary resuscitation resulted in significantly higher levels of left ventricular myocardial blood flow than either vasopressin alone or epinephrine alone. Epinephrine 274-285 arginine vasopressin Homo sapiens 110-121 1683267-5 1991 Inhibition was dose-dependent and restricted to the alpha 2-adrenoceptor mediated aggregation response stimulated by epinephrine (1 microM) or potentiated by subthreshold concentrations of epinephrine (30-300 nM) in the presence of subaggregatory doses of vasopressin (10-30 nM). Epinephrine 189-200 arginine vasopressin Homo sapiens 256-267 8633820-1 1996 BACKGROUND: Successful outcomes after cardiopulmonary resuscitation remain disappointingly infrequent, in animal studies, administration of exogenous vasopressin during closed- and open-chest cardiopulmonary resuscitation has recently been shown to be more effective than optimal doses of epinephrine in improving vital organ blood flow. Epinephrine 289-300 arginine vasopressin Homo sapiens 150-161 3394838-6 1988 Vasopressin increased from 1.2 +/- 0.3 to 137 +/- 45 pg/ml and renin activity increased from 1.45 +/- 4.0 to 3.80 +/- 1.0 ng.ml-1.h-1 with no further changes in epinephrine, norepinephrine, and vasoactive intestinal polypeptide. Epinephrine 161-172 arginine vasopressin Homo sapiens 0-11 2046887-5 1991 Vasopressin also caused decrease of Epinephrine (E) from both the innervated (68-73%) and denervated (69-74%) glands 0.5 and 4 h after injection indicating that the splanchnic nerve has no effect on vasopressin-induced release of E. Accelerated resynthesis of NE exceeding the control value (44-94%) was encountered 144 and 216 h after injection as compared to a slower increase (14%) in denervated glands 216 h after injection. Epinephrine 36-47 arginine vasopressin Homo sapiens 0-11 2899848-8 1988 Results of this study support the hypothesis that epinephrine and/or norepinephrine regulate the release of ACTH and vasopressin via alpha-1- and alpha-2-adrenergic receptors associated with CRF- and VP-containing somata within the PVN. Epinephrine 50-61 arginine vasopressin Homo sapiens 117-128 3490977-11 1986 Adrenaline also enhances the extent of [3H]5HT secretion induced by U46619, thrombin and vasopressin but fails to increase that induced by ADP in this aspirin-treated preparation. Epinephrine 0-10 arginine vasopressin Homo sapiens 89-100 2822307-8 1987 Low dose adrenaline infusion (0.013 microgram/kg per min) does not cause ACTH or cortisol release, but appears to blunt the ACTH and cortisol rise caused by arginine vasopressin (0.14 pressor units/kg, i.m. Epinephrine 9-19 arginine vasopressin Homo sapiens 166-177 2953085-0 1987 V1a-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation. Epinephrine 79-90 arginine vasopressin Homo sapiens 4-15 2953085-3 1987 Aggregating effect of VP on human platelets was potentiated by both ADP and epinephrine. Epinephrine 76-87 arginine vasopressin Homo sapiens 22-24 3490977-8 1986 Adrenaline, when added prior to non-saturating concentrations of U46619, thrombin, vasopressin or ADP, significantly enhances the increase in cytosolic [Ca2+] induced by these agonists in platelets suspended in media containing less than 0.1 microM or 1 mM Ca2+. Epinephrine 0-10 arginine vasopressin Homo sapiens 83-94 3593215-2 1987 This study investigated the effects of sub-threshold concentrations of adrenaline (0.1-1 microM) on vasopressin (10 nM-1 microM)-induced platelet aggregation, ATP secretion, elevation of cytosolic free Ca2+ concentration ([Ca2+]i) and hydrolysis of inositol phospholipids, monitored as [32P]phosphatidic acid formation. Epinephrine 71-81 arginine vasopressin Homo sapiens 100-111 3593215-3 1987 Potentiation of vasopressin-induced aggregation and ATP secretion by adrenaline was accompanied by enhanced elevation of [Ca2+]i and [32P]phosphatidic acid formation. Epinephrine 69-79 arginine vasopressin Homo sapiens 16-27 3593215-4 1987 The stimulatory effects of adrenaline on vasopressin-induced platelet activation were mimicked by the combination of the Ca2+ ionophore, ionomycin, and the protein kinase C activator, phorbol 12-myristate 13-acetate, but not by either of these agents alone. Epinephrine 27-37 arginine vasopressin Homo sapiens 41-52 3593215-5 1987 These results suggest that the potentiation of vasopressin-induced platelet activation by adrenaline is mediated via enhancement of inositol phospholipid hydrolysis and elevation of [Ca2+]i. Epinephrine 90-100 arginine vasopressin Homo sapiens 47-58 6281092-2 1982 Adrenaline and D2O reduced the interaction between ADH and its receptors. Epinephrine 0-10 arginine vasopressin Homo sapiens 51-54 3709811-2 1986 Glucagon and epinephrine stimulated [U-14C]palmitate oxidation to ketone bodies by 60 and 25% as early as at 1 h. The stimulatory effects were almost totally prevented by the simultaneous presence of vasopressin, phorbol 12-tetradecanoate 13-acetate (TPA), or diacylglycerol (1-oleoyl-2-acetylglycerol). Epinephrine 13-24 arginine vasopressin Homo sapiens 200-211 6126864-3 1982 Release of LHRH, somatostatin and vasopressin is affected by a variety of neurotransmitters or neuromodulators, such as norepinephrine, dopamine, epinephrine, histamine, cholinergic and opioid agonists, and peptides such as angiotensin II. Epinephrine 123-134 arginine vasopressin Homo sapiens 34-45 14219827-0 1964 [REINFORCING EFFECT OF ADRENALINE ON ANTIDIURESIS INDUCED BY VASOPRESSIN]. Epinephrine 23-33 arginine vasopressin Homo sapiens 61-72 31646370-10 2019 In norepinephrine-refractory patients, vasopressin or epinephrine may be added. Epinephrine 6-17 arginine vasopressin Homo sapiens 39-50 31334620-0 2019 Atropine or adrenaline plus atropine may constitute appropriate treatment for cardiac arrest caused by intramyometrial injection of vasopressin. Epinephrine 12-22 arginine vasopressin Homo sapiens 132-143 30232658-0 2018 Publisher Correction: Exposure to Stress-Dose Steroids and Lethal Septic Shock After In-Hospital Cardiac Arrest: Individual Patient Data Reanalysis of Two Prior Randomized Clinical Trials that Evaluated the Vasopressin-Steroids-Epinephrine Combination Versus Epinephrine Alone. Epinephrine 228-239 arginine vasopressin Homo sapiens 207-218 30232658-0 2018 Publisher Correction: Exposure to Stress-Dose Steroids and Lethal Septic Shock After In-Hospital Cardiac Arrest: Individual Patient Data Reanalysis of Two Prior Randomized Clinical Trials that Evaluated the Vasopressin-Steroids-Epinephrine Combination Versus Epinephrine Alone. Epinephrine 259-270 arginine vasopressin Homo sapiens 207-218 30084038-0 2018 Exposure to Stress-Dose Steroids and Lethal Septic Shock After In-Hospital Cardiac Arrest: Individual Patient Data Reanalysis of Two Prior Randomized Clinical Trials that Evaluated the Vasopressin-Steroids-Epinephrine Combination Versus Epinephrine Alone. Epinephrine 206-217 arginine vasopressin Homo sapiens 185-196 28754320-0 2017 Efficacy of vasopressin-epinephrine compared to epinephrine alone for out of hospital cardiac arrest patients: A systematic review and meta-analysis. Epinephrine 24-35 arginine vasopressin Homo sapiens 12-23 28754320-1 2017 OBJECTIVE: The aim of this study was to conduct a meta-analysis to evaluate the efficacy of vasopressin-epinephrine compared to epinephrine alone in patients who suffered out-of-hospital cardiac arrest (OHCA). Epinephrine 104-115 arginine vasopressin Homo sapiens 92-103 28754320-2 2017 METHODS: Relevant studies up to February 2017 were identified by searching in PubMed, EMBASE, the Cochrane Library, Wanfang for randomized controlled trials(RCTs) assigning adults with cardiac arrest to treatment with vasopressin-epinephrine (VEgroup) vs adrenaline (epinephrine) alone (E group). Epinephrine 230-241 arginine vasopressin Homo sapiens 218-229 28754320-7 2017 Subgroup showed that vasopressin-epinephrine has a significant association with improvements in ROSC for patients from Asia (OR=3.30, 95% CI=1.30-7.88); but for patients from other regions, there was no difference between vasopressin-epinephrine and epinephrine alone (OR=1.07, 95% CI=0.72-1.61). Epinephrine 33-44 arginine vasopressin Homo sapiens 21-32 28754320-7 2017 Subgroup showed that vasopressin-epinephrine has a significant association with improvements in ROSC for patients from Asia (OR=3.30, 95% CI=1.30-7.88); but for patients from other regions, there was no difference between vasopressin-epinephrine and epinephrine alone (OR=1.07, 95% CI=0.72-1.61). Epinephrine 33-44 arginine vasopressin Homo sapiens 222-233 26767546-8 2015 Although no significant difference was observed between two groups, but survival rates after hospital discharge in group that receiving vasopressin-epinephrine was significantly higher than those patients that only got only epinephrine. Epinephrine 148-159 arginine vasopressin Homo sapiens 136-147 25541224-0 2015 Should unobstructed gasping be facilitated and confirmed before administering adrenaline, otherwise, give titrated vasopressin? Epinephrine 78-88 arginine vasopressin Homo sapiens 115-126 24871568-3 2014 OBJECTIVE: Determine if vasopressin therapy in combination with epinephrine was associated with improved outcomes in patients with cardiac arrest compared to epinephrine alone. Epinephrine 158-169 arginine vasopressin Homo sapiens 24-35 24871568-10 2014 Subgroup analysis of ROSC in patients with an arterial pH of <7.2 (n = 35) showed an increased rate of ROSC (63% vs 37%, P = 0.01) in the vasopressin plus epinephrine group versus the epinephrine alone group, respectively. Epinephrine 187-198 arginine vasopressin Homo sapiens 141-152 24871568-12 2014 CONCLUSIONS: Vasopressin in combination with epinephrine demonstrated improved ROSC in cardiac arrest patients with initial arterial pH <7.2 compared with epinephrine alone, without improving survival to hospital discharge. Epinephrine 158-169 arginine vasopressin Homo sapiens 13-24 24064875-8 2013 RESULTS: We found that vasopressin (p = 0.005) and epinephrine (p = 0.01) increased significantly with injury, while angiotensin (p = 0.60) and cortisol (p = 0.46) did not and that vasopressin (p < 0.001) and epinephrine (p = 0.004) increased significantly in patients requiring transfusion of more than 600 mL but angiotensin II (p = 0.11) and cortisol (p = 0.90) did not. Epinephrine 212-223 arginine vasopressin Homo sapiens 23-34 22766618-9 2012 The use of several inotropes or vasopressor such as vasopressin is proposed in case of reactions refractory to epinephrine and volume expansion. Epinephrine 111-122 arginine vasopressin Homo sapiens 52-63 22234076-8 2011 Although there was no retching or vomiting, 80% of patients presented with nausea and exhibited a significant increase in plasma levels of VP, adrenaline and noradrenaline after administration of VP analogue. Epinephrine 143-153 arginine vasopressin Homo sapiens 196-198 21926888-4 2011 The purpose of this retrospective case series was to report successful return of spontaneous circulation after the rescue administration of vasopressin after prolonged CA and failure of conventional CPR, advanced life support, and epinephrine therapy in children. Epinephrine 231-242 arginine vasopressin Homo sapiens 140-151 23860985-1 2013 IMPORTANCE: Among patients with cardiac arrest, preliminary data have shown improved return of spontaneous circulation and survival to hospital discharge with the vasopressin-steroids-epinephrine (VSE) combination. Epinephrine 184-195 arginine vasopressin Homo sapiens 163-174 23860985-12 2013 CONCLUSION AND RELEVANCE: Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with epinephrine/saline placebo, resulted in improved survival to hospital discharge with favorable neurological status. Epinephrine 106-117 arginine vasopressin Homo sapiens 94-105 23860985-12 2013 CONCLUSION AND RELEVANCE: Among patients with cardiac arrest requiring vasopressors, combined vasopressin-epinephrine and methylprednisolone during CPR and stress-dose hydrocortisone in postresuscitation shock, compared with epinephrine/saline placebo, resulted in improved survival to hospital discharge with favorable neurological status. Epinephrine 225-236 arginine vasopressin Homo sapiens 94-105 21926666-0 2012 Vasopressin rescue for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing: a prospective feasibility pilot trial. Epinephrine 101-112 arginine vasopressin Homo sapiens 0-11 21926666-1 2012 OBJECTIVES: To assess the feasibility of a large, randomized controlled trial of combination epinephrine-arginine vasopressin for in-pediatric intensive care unit cardiopulmonary arrest refractory to initial epinephrine dosing. Epinephrine 93-104 arginine vasopressin Homo sapiens 114-125